HOVILPRI Dosing & Administration

HOVILPRI—once-daily oral dosing¹

Once-daily oral dosing—initiate treatment with a loading dose of 400 mg (four 100-mg tablets) on Day 1, followed by a maintenance dose of 100 mg (1 tablet) daily by mouth, with or without food, until herpes simplex virus (HSV) lesions have healed¹

No renal dose adjustment is recommended for patients with mild, moderate, or severe renal impairment. The pharmacokinetics and safety of pritelivir in patients requiring hemodialysis have not been evaluated¹

Can be self-administered and taken in both outpatient and inpatient settings²

Potential drug interactions¹

Proton pump inhibitors

Avoid concomitant use of

Esomeprazole and rabeprazole
Omeprazole and lansoprazole at daily doses >20 mg
Pantoprazole at daily doses >40 mg

Histamine-2 (H2)-receptor antagonists

HOVILPRI should be given at least 2 hours before or 12 hours after H2-receptor antagonists

Antacids

Separate any dosing of antacids from HOVILPRI dosing by 2 hours

Breast cancer resistance protein (BCRP) substrates

Coadministration with HOVILPRI may increase plasma concentrations of BCRP substrates and the risk of adverse reactions
For additional information on coadministered drugs, refer to the Prescribing Information

Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F)¹

HOVILPRI (pritelivir) tablet, stylized product photo (not actual size) — placeholder (FPO); replace and re-confirm alt text once the final image is set.

Tablet not actual size.

H2, histamine-2; HSV, herpes simplex virus; MOA, mechanism of action.

References: 1. HOVILPRI. Prescribing information. Asahi Kasei Therapeutics. 2. Data on file. Asahi Kasei Therapeutics.

Important Safety Information

Warnings and Precautions

Drug Interactions With Acid-Reducing Agents: Concomitant use of HOVILPRI with certain acid-reducing agents may reduce pritelivir exposure, potentially resulting in reduced therapeutic effect and development of resistance. Avoid concomitant use with certain proton pump inhibitors, and stagger concomitant use with H2-receptor antagonists and antacids.

Adverse Reactions: In clinical studies, the adverse reaction (all grades) occurring in more than 5% of participants receiving HOVILPRI was headache, which occurred in 6% and 4% of the HOVILPRI and investigator’s choice participants, respectively.

Drug Interactions:

Pritelivir is a breast cancer resistance protein (BCRP) inhibitor. Co-administration of HOVILPRI with a BCRP substrate may increase the plasma concentrations of the BCRP substrate, which may increase the risk of adverse reactions.

Concomitant use of acid-reducing agents may elevate gastric pH and decrease the systemic bioavailability of HOVILPRI, which may reduce its effectiveness or cause drug resistance to HOVILPRI. Avoid concomitant use with esomeprazole or rabeprazole. Avoid concomitant use with omeprazole or lansoprazole at daily doses above 20 mg, or with pantoprazole at daily doses above 40 mg. Take HOVILPRI at least 2 hours before or 12 hours after H2-receptor antagonists. Take HOVILPRI at least 2 hours before or 2 hours after antacids.

How are HOVILPRI^® (pritelivir) tablets administered?